




INDO US
BIO-TECH LIMITED
(AN ISO CERTIFIED COMPANY)
CIN LO1122GJ2004PLC043550



Date: 13/11/2020

To,
The Deputy Manager,
The Department of Corporate Services,
Bombay Stock Exchange Limited,
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Company Code-541304

SUB: Declaration of Financial Results for the half year ended on 30th September, 2020.
Reference: Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015.


Dear Sir,


With reference to captioned subject and pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Unaudited Financial Results, Provisional Balance Sheet, Profit and Loss Account and Cash Flow Statement for the Quarter and Half year ended on 30th September, 2020, along with Limited Review Report for the half year ended on 30th September, 2020.

Kindly take the same on your record and oblige us.

Thanking you,

For, Indo Us Bio Tech Limited



Mr. Jagdish Ajudia
Managing Director
(DIN: 01745951)



Regd. Office :
309, Shanti Mall, Sattadhar Cross Road,
Opp. Navrang Tower, Ahmedabad-380 061.
Tele Fax : +91-079-27491807,
Mobile : +91-9909043999

DSIR RECOGNITION IN HOUSE R&D UNIT
Factory Address :
Village-Bardoli Kanthi,
Near Indira Nagar, Ta.-Dehgam,
Dist-Gandhinagar, Gujarat.

E-mail : indousexim@gmail.com • Web : www.indousagriseeds.com







INDO US

BIO-TECH LIMITED

(AN ISO CERTIFIED COMPANY)
CIN LO1122GJ2004PLC043550



Indo US Bio-Tech Limited					
Statement of standalone unaudited financial results for the half year ended ended on 30th September 2020					
(Amount in Rs)					
PARTICULARS	Half year ended			Year ended	
	30-09-2020 (Unaudited)	31-03-2020 (Audited)	30-09-2019 (Unaudited)	31-03-2020 (Audited)	
I	Income				
	Revenue from operations	16,86,88,303	21,73,70,960	18,02,42,818	39,76,13,778
	Other income	21,923	43,994	34,532	78,526
	Total income from operations	16,87,10,226	21,74,14,954	18,02,77,350	39,76,92,304
II	Expenses				
	Purchases	73,13,993	1,64,53,890	1,94,75,033	3,59,28,923
	Production Expenses	12,87,24,844	15,90,60,553	10,77,25,060	26,67,85,613
	Change in Inventories	(82,94,176)	(10,61,793)	1,67,14,362	1,56,52,569
	Employee benefit expenses	31,80,868	23,88,822	33,11,206	57,00,028
	Finance costs	53,57,492	45,70,874	42,67,849	88,38,723
	Depreciation and amortization expenses	11,65,951	11,71,713	11,08,761	22,80,474
	Other expenses	1,57,77,245	2,11,02,844	1,26,63,916	3,37,66,760
	Total expenses	15,32,26,217	20,36,86,903	16,52,66,187	36,89,53,090
III	Profit/(Loss) before exceptional items and tax	1,54,84,009	1,37,28,051	1,50,11,163	2,87,39,214
IV	Exceptional items- Prior Period Items		1,01,383		1,01,383
V	Profit/(Loss) before tax	1,54,84,009	1,36,26,668	1,50,11,163	2,86,37,831
VI	Tax expenses				
	a) Current tax	5,26,000	7,05,800	15,02,000	22,07,800
	b) Income tax prior year			10,95,935	3,00,230
	b) Deferred tax	1,38,400	(3,13,396)	3,00,230	7,82,539
	Total tax expenses	6,64,400	3,92,404	28,98,165	32,90,569
VII	Net Profit/(Loss) for the period/year	1,48,19,609	1,32,34,264	1,21,12,998	2,53,47,262
VIII	Other comprehensive income (net of tax)				
	Items that will not be reclassified to profit or loss:				
	i) Remeasurement of post employment benefit obligations	-	-	-	-
	ii) Income-tax relating to items that will not be reclassified to profit or loss	-	-	-	-
	Total other comprehensive income	-	-	-	-
IX	Total comprehensive income for the period/year (VII+VIII)	1,48,19,609	1,32,34,264	1,21,12,998	2,53,47,262
X	Paid-up equity share capital (face value of Rs.10 per share)	10	10	10	10
XI	Other equity (excluding revaluation reserve)	11,85,62,752	10,37,43,143	90,58,879	10,37,43,143
XII	EPS in Rs. (Face Value of Rs.10/- each)*				
	-Basic	2.44	2.18	2.00	4.18
	-Diluted	2.44	2.18	2.00	4.18
	*not annualised				



Regd. Office :
309, Shanti Mall, Sattadhar Cross Road,
Opp. Navrang Tower, Ahmedabad-380 061.
Tele Fax : +91-079-27491807,
Mobile : +91-9909043999


DSIR RECOGNITION IN HOUSE
Factory Address :
Village-Bardoli Kanthi,
Near Indira Nagar, Ta.-Dehgam,
Dist-Gandhinagar, Gujarat.

E-mail : indousexlm@gmail.com • Web : www.indousagriseeds.com



INDO US BIO-TECH LIMITED

(AN ISO CERTIFIED COMPANY)
CIN LO1122GJ2004PLC043550



Notes

(1) The financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 13th November 2020 and the Statutory Auditors of the Company have expressed an unmodified opinion on these results.


(2) The company is dealing in one major product segment, i.e. Seed Cultivation.

(3) The outbreak of Coronavirus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activities. Measures taken to contain the spread of the virus including travel ban, quarantine, social distancing, and closure of non-essential services have triggered significant disruptions resulting in an economic slowdown. The Government ordered a national wide lockdown to prevent community spread of COVID-19 in India resulting in significant reduction in economic activities. The company caters to the farmers which is one of the most essential input for them. The capacity utilization of the plants has been affected due to various factors like unavailability of labour, disrupted supplies of packing material, delays in movement of trucks affecting inward and outward supply of seeds. However, the company has been able to undertake operations under most protected conditions and thus having not much of the impact due to COVID-19 pandemic.

In assessing the recoverability of company's assets such as trade receivable, inventories, etc. the company has considered internal and external information up to the date of approval of these financial results. Based on the current indicators of future economic conditions, the management expects to recover the carrying amount as at 30th September 2020 of the assets. However, the management will continue to closely monitor the evolving situation and assess its impact on the business of the Company.

(4) The figures have been regrouped/rearranged wherever necessary.

For and on behalf of Board of Directors


Jagdish D Ajudiya
Managing Director
DIN: 01745951



Place: Ahmedabad
Date: 13th November 2020



GAUTAM N ASSOCIATES
CHARTERED ACCOUNTANTS

(PARTNER)

UDIN:-20032742AAAAL62892



Regd. Office :
309, Shanti Mall, Sattadhar Cross Road,
Opp. Navrang Tower, Ahmedabad-380 061.
Tele Fax : +91-079-27491807,
Mobile : +91-9909043999

DSIR RECOGNITION IN HOUSE R&D UNIT
Factory Address :
Village-Bardoli Kanthi,
Near Indira Nagar, Ta.-Dehgam,
Dist-Gandhinagar, Gujarat.


E-mail : indousexim@gmail.com • Web : www.indousagriseeds.com



INDO US

BIO-TECH LIMITED

(AN ISO CERTIFIED COMPANY)
CIN LO1122GJ2004PLC043550




Indo US Bio-Tech Limited			Amount in	Amount in
Balance Sheet as at 30th September, 2020 (Provisional)			30-Sep-20	31-Mar-20
	Note			
EQUITY AND LIABILITIES				
Shareholders' funds				
(a) Share capital	02		6,06,79,900	6,06,79,900
(b) Reserves and surplus	03		11,85,62,752	10,37,43,143
			17,92,42,652	16,44,23,043
Share application money pending allotment				
Non-current liabilities				
(a) Long-term borrowings	04		3,34,46,526	49,06,026
(b) Deferred tax liability (net)			8,33,027	6,94,627
(c) Long-term provisions	06		6,36,894	5,24,259
(d) Other Non-current liabilities	07		65,04,055	60,39,232
			4,14,20,502	1,21,64,144
Current liabilities				
(a) Short-term borrowings	08		6,67,98,558	7,37,58,922
(b) Trade payables	09			
i) total outstanding dues of micro and small enterprises			2,47,37,118	7,93,86,414
ii) total outstanding dues of other than micro and small enterprises			11,00,000	1,32,79,472
(c) Other current liabilities	10		50,31,594	39,56,160
(d) Short-term provisions	11		9,76,67,270	17,03,80,968
			31,83,30,424	34,69,68,155
ASSETS				
Non-current assets				
(a) Property, Plant & Equipments	11		1,39,01,510	1,40,82,156
Tangible assets				
Intangible assets	11		1,28,37,384	1,27,60,541
Capital work-in-progress				
Intangible assets under development				
(b) Non-current investments	12			
(c) Deferred tax assets (Net)	13		7,16,778	8,33,241
(d) Long-term loans and advances	14		2,16,438	2,88,584
(e) Other Non-current Assets			2,76,72,110	2,79,64,522
Current assets				
(a) Current investments	15		9,97,73,726	9,14,79,550
(b) Inventories	16		17,17,09,313	20,97,68,431
(c) Trade receivables	17		67,56,075	20,04,329
(d) Cash and cash equivalents	18		1,14,53,693	1,52,25,545
(e) Short-term loans and advances	19		9,66,507	5,25,778
(f) Other Current Assets			29,06,58,313	31,90,03,633
			31,83,30,424	34,69,68,155

Summary of significant accounting policies 1 to 34
The accompanying notes are an integral part of the financial statements.
As per our report of even date

For Gautam N Associates
Chartered Accountants
F.R.No: 10311794
Gautam
Gautam Nandawat
Partner
M.No: 32742
UDIN: 20032742AAAA 2807



For and on behalf of Board of Directors
Jagdish D. Ajudiya
Jagdish D. Ajudiya
Managing Director
DIN: 01745591
Priyanka J. Ajudiya
Priyanka J. Ajudiya
Executive Director
DIN: 07941023




Place :- Ahmedabad
Date :- 13/11/2020

Regd. Office :
309, Shanti Mall, Sattadhar Cross Road,
Opp. Navrang Tower, Ahmedabad-380 061.
Tele Fax : +91-079-27491807,
Mobile : +91-9909043999

D&IR RECOGNITION IN HOUSE R&D UNIT
Factory Address :
Village-Bardoli Kanthi,
Near Indira Nagar, Ta.-Dehgam,
Dist-Gandhinagar, Gujarat.

E-mail : indousexim@gmail.com • Web : www.indousagriseeds.com






INDO US

BIO-TECH LIMITED

(AN ISO CERTIFIED COMPANY)
CIN LO1122GJ2004PLC043550



Indo US Bio-Tech Limited			
Statement of Profit & Loss Account For the Half Year Ended on 30th September, 2020 (Provisional)			
	Note	Amount In	Amount In
		30-Sep-2020	31-Mar-2020
INCOME			
Revenue From Operations	20	16,86,88,303	39,76,13,778
Other Income	21	21,923	78,526
Total Revenue (I)		16,87,10,226	39,76,92,304
EXPENSES			
Purchases of Stock in Trade	22	73,13,993	3,59,28,923
Production Expenses	23	12,87,24,844	26,67,85,613
Changes in Inventories	24	(82,94,176)	1,56,52,569
Employee benefits expenses	25	31,80,868	57,00,028
Finance costs	26	53,57,492	88,38,723
Depreciation and amortization expense			
(i) Depreciation for the year		10,93,805	21,36,182
(ii) Preliminary Expenses W/off		72,146	1,44,292
Other expenses	27	1,57,77,245	3,37,66,760
Total expenses (ii)		15,32,26,217	36,89,53,090
Profit before extraordinary items, Prior Period Items & tax		1,54,84,009	2,87,39,214
Prior Period Expenses			1,01,383
Extraordinary Items			-
Profit before tax		1,54,84,009	2,86,37,831
Tax expense:			
Current tax		5,26,000	22,07,800
Deferred tax		1,38,400	7,82,539
Short / (Excess) Provision			3,00,230
Profit (Loss) for the period		1,48,19,609	2,53,47,262
Earnings per equity share:			
(1) Basic	28	2.44	4.18
(2) Diluted		2.44	4.18

Summary of significant accounting policies 1 to 34
The accompanying notes are an integral part of the financial statements.
As per our report of even date

For Gautam N Associates
Chartered Accountants
F.R.No: 103117W

Gautam Nandawat
Partner
M.No : 32742
UDIN : 20032742AAALS2892

Place :- Ahmedabad
Date :- 13/11/2020



For and on behalf of Board of Directors
Indo US Bio-Tech Limited

Jagdish D. Ajudiya
Managing Director
DIN: 01745561

Priyanka J. Ajudiya
Executive Director
DIN: 07941023



Regd. Office :
309, Shanti Mall, Sattadhar Cross Road,
Opp. Navrang Tower, Ahmedabad-380 061.
Tele Fax : +91-079-27491807,
Mobile : +91-9909043999

DSIR RECOGNITION IN HOUSE R&D UNIT
Factory Address :
Village-Bardoli Kanthi,
Near Indra Nagar, Ta.-Dehgam,
Dist-Gandhinagar, Gujarat.

E-mail : indousexim@gmail.com • Web : www.indousagriseeds.com



INDO US



BIO-TECH LIMITED

(AN ISO CERTIFIED COMPANY)
CIN LO1122GJ2004PLC043550



Cash Flow Statement for the Half Year ended on 30th September 2020

	Amount In 30-Sep-2020	Amount In 31-Mar-2020
Cash flow from operating activities:		
Net profit before tax as per statement of profit and loss	1,54,84,009	2,86,37,831
Adjusted for:		
Preliminary expenses	72,146	1,44,292
Provision for gratuity	90,985	1,81,970
Depreciation & amortization	10,93,805	21,36,182
Asset written off during the year	-	54,229
Interest income on loans & advances given	-	(300)
Interest & finance costs	53,57,492	88,38,723
Operating cash flow before working capital changes	2,20,98,437	3,99,92,927
Adjusted for:		
(Increase)/ decrease in inventories	(82,94,176)	1,56,52,569
(Increase)/ decrease in trade receivables	3,80,60,118	(11,91,62,364)
(Increase)/ decrease in other current assets	(4,40,729)	(1,03,885)
(Increase)/ decrease in other non current assets	-	-
Increase/ (decrease) in other non current liabilities	4,64,823	1,09,483
Increase/ (decrease) in trade payables	(5,46,49,296)	5,87,15,499
Increase/ (decrease) in other current liabilities	(1,21,79,472)	15,68,744
Increase/ (decrease) in long term provisions	1,12,635	1,67,011
Increase/ (decrease) in short term provisions	4,58,449	(44,94,511)
Cash generated from / (used in) operations	(1,43,69,210)	(75,54,527)
Income taxes paid	-	(3,00,230)
Net cash generated from/ (used in) operating activities [A]	(1,43,69,210)	(78,54,757)
Cash flow from investing activities:		
Purchase of fixed assets	(9,90,004)	(39,61,861)
Sales of fixed assets	-	3,38,999
Increase/ decrease in short term loans and advances	37,71,852	(20,46,531)
Increase/ decrease in long term loans and advances	1,16,463	(2,00,000)
Interest income on loans & advances given	-	300
Net cash flow from/(used) in investing activities [B]	28,98,311	(58,69,093)
Cash flow from financing activities:		
Proceeds from issue of equity shares / Addition in Capital	-	(16,87,218)
Proceeds from long term borrowing (net)	2,85,40,500	2,54,32,599
Proceeds from short term borrowing (net)	(69,60,364)	(88,38,723)
Interest & finance costs	(53,57,492)	-
Net cash flow from/(used in) financing activities [C]	1,62,22,645	1,49,06,658
Net increase/(decrease) in cash & cash equivalents [A+B+C]	47,51,745	11,82,808
Cash & cash equivalents as at beginning of the year	20,04,329	8,21,521
Cash & cash equivalents as at end of the year [Refer Note No.17]	67,56,074	20,04,329



Regd. Office :
309, Shanti Mall, Sattadhar Cross Road,
Opp. Navrang Tower, Ahmedabad-380 061.
Tele Fax : +91-079-27491807,
Mobile : +91-9909043999


DSIR RECOGNITION IN HOUSE R&D UNIT
Factory Address :
Village-Bardoli Kanthi,
Near Indira Nagar, Ta.-Dehgam,
Dist-Gandhinagar, Gujarat.

E-mail : indousexim@gmail.com • Web : www.indousagriseeds.com




INDO US BIO-TECH LIMITED

(AN ISO CERTIFIED COMPANY)
CIN LO1122GJ2004PLC043550



As per our report of even date


For Gautam N Associates
Chartered Accountants
F.R.No: 103117W



Gautam Nandawat
Partner
M.No : 032742
UDIN : 20032742AAAALS2392



Place :- Ahmedabad
Date :- 13-11-2020



For and on behalf of Board of Directors


Jagdish D. Ajudiya
Managing Director
DIN\01745951


Priyanka V. Ajudiya
Executive Director
DIN: 07941023



Regd. Office :
309, Shanti Mall, Saitadhar Cross Road,
Opp. Navrang Tower, Ahmedabad-380 061.
Tele Fax : +91-079-27491807,
Mobile : +91-9909043899

DSIR RECOGNITION IN HOUSE R&D UNIT
Factory Address :
Village-Bardoli Kanthi,
Near Indira Nagar, Ta.-Dehgam,
Dist-Gandhinagar, Gujarat.

E-mail : indousexim@gmail.com • Web : www.indousagriseeds.com




LIMITED REVIEW REPORT

To,
The Board of Directors
Indo US Bio-Tech Limited
Ahmedabad

1. We have reviewed the accompanying statement of unaudited financial results of Indo US Bio-Tech Limited for the half year ended 30th September 2020, Assets Liability Statement and Cash Flow Statement ("The Statement") being submitted by the Company pursuant to the requirements of regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015 as modified.
2. This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Ind-AS 34- 'Interim Financial Reporting' prescribed under section 133 of the Companies Act., 2013 read with relevant rules issued there under and other recognised accounting practices and policies generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Gautam N Associates
Chartered Accountants
FRN: 103117W



Gautam N Associates
M No: 032742

UDIN: 20032742AAAALS2892



Place: Ahmedabad
Date: 13th November 2020